Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-25-081480
Filing Date
2025-04-15
Accepted
2025-04-15 16:00:30
Documents
21
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d903210d10ka.htm   iXBRL 10-K/A 663192
2 EX-31.1 d903210dex311.htm EX-31.1 2937
3 EX-31.2 d903210dex312.htm EX-31.2 2790
9 GRAPHIC g903210g0415043204074.jpg GRAPHIC 26141
10 GRAPHIC g903210g0415043204465.jpg GRAPHIC 27266
  Complete submission text file 0001193125-25-081480.txt   1789731

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA jagx-20241231.xsd EX-101.SCH 5788
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE jagx-20241231_cal.xml EX-101.CAL 685
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE jagx-20241231_def.xml EX-101.DEF 18602
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20241231_lab.xml EX-101.LAB 23970
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20241231_pre.xml EX-101.PRE 19791
23 EXTRACTED XBRL INSTANCE DOCUMENT d903210d10ka_htm.xml XML 312974
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36714 | Film No.: 25839410
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)